Research reveals widespread use of ineffective COVID-19 treatments after FDA deauthorized their use
Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms
29 August 2022Study reveals mechanism involved in rare pediatric brain cancer and points to possible treatment
29 August 2022Research reveals widespread use of ineffective COVID-19 treatments after FDA deauthorized their use
Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use authorization for two monoclonal antibodies (bamlanivimab/etesevimab and casirivimab/imdevimab) for the treatment of mild to moderate COVID-19 in high-risk, non-hospitalized patients. However, these treatments were shown not to work against the omicron variant of COVID-19, which emerged in the United States in December 2021 and was responsible for a record-breaking COVID-19 surge in the winter of 2021–22. As a result of the monoclonal antibodies’ reduced efficacy against the variant, the FDA deauthorized their use in early January 2022.
